enGene Therapeutics
ENGN
ENGN
61 hedge funds and large institutions have $382M invested in enGene Therapeutics in 2026 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
28% less capital invested
Capital invested by funds: $530M → $382M (-$148M)
Holders
61
Holding in Top 10
3
Calls
–
Puts
–
Top Buyers
| 1 | +$17.1M | |
| 2 | +$10.2M | |
| 3 | +$9.88M | |
| 4 |
BOCH
Blue Owl Capital Holdings
New York
|
+$9.4M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$3.11M |
Top Sellers
| 1 | -$36.1M | |
| 2 | -$17.1M | |
| 3 | -$8.58M | |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
-$6M |
| 5 |
Morgan Stanley
New York
|
-$5.63M |
